Neurology

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial…

8 months ago
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial PreparationOragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel…

8 months ago
Dr. Satjit Bhusri Sworn in as Honorary Police Surgeon for the NYPDDr. Satjit Bhusri Sworn in as Honorary Police Surgeon for the NYPD

Dr. Satjit Bhusri Sworn in as Honorary Police Surgeon for the NYPD

Leading Cardiologist Recognized for Contributions to Cardiology and Public Service NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024…

8 months ago
New Study Confirms the Accuracy of BrainCheck Assess in Comparison with Widely-Used Montreal Cognitive Assessment (MoCA)New Study Confirms the Accuracy of BrainCheck Assess in Comparison with Widely-Used Montreal Cognitive Assessment (MoCA)

New Study Confirms the Accuracy of BrainCheck Assess in Comparison with Widely-Used Montreal Cognitive Assessment (MoCA)

Study published in Frontiers in Psychology shows BrainCheck Assess is a reliable and accurate digital cognitive assessment AUSTIN, Texas, Oct. 8,…

8 months ago
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments…

8 months ago
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic ComplicationsZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four…

8 months ago